Why Do Gray-Market Peptide Sellers Only Take Crypto?

What Did the Chainalysis Report Find?

Blockchain analytics firm Chainalysis published a report on 4 June 2026 tracking cryptocurrency wallets tied to sellers of unregulated, unapproved peptides — the same broad category covering wellness compounds like BPC-157 and TB-500, GLP-1-class compounds, and cosmetic peptides such as melanotan. The firm found inflows to these vendors have grown for six consecutive quarters and are on pace to cross a $100 million annual run rate in 2026, up from roughly $1 million a quarter as recently as 2024. Quarter-on-quarter growth accelerated sharply into 2026: inflows rose from about $12 million in Q4 2025 to roughly $32 million in Q1 2026, a 159% jump, as reported by Fortune and The Block.[1][2]

The headline reason vendors transact almost exclusively in bitcoin and stablecoins rather than cards or bank transfers is straightforward: traditional payment processors routinely decline transactions involving unregulated or prescription-grade compounds, and crypto rails offer sellers a channel banks won't provide.[1] That is a story about payment infrastructure, not about the research use of any individual compound — but it has a direct bearing on how researchers should think about vendor trust.

Where Is the Supply Actually Coming From?

The more striking finding in the Chainalysis dataset, as summarised by Fortune's reporting on the underlying data, is provenance. Some of the Chinese chemical manufacturers now selling wellness and weight-loss-adjacent peptides directly to retail buyers online previously supplied fentanyl and amphetamine precursor chemicals to transnational trafficking networks.[2] Retail customers transacting with anonymous, crypto-only vendors have essentially no way of knowing this history, or of verifying what a given vial actually contains.

This is a distinct story from the counterfeit-manufacturing and organised-crime reporting we've covered separately — our report on MHRA's illegal UK manufacturing raids and on organised counterfeit retatrutide distribution both concern physical product entering the UK street market. The Chainalysis data is about the financial rails funding the wider, largely US-facing online gray market for wellness peptides.

Why Does an Unverified Supply Chain Matter for Research Quality?

Separately, a 16 September 2026 Johns Hopkins University Hub piece quoted Christopher Robinson, a physician-scientist at the Johns Hopkins University School of Medicine, on the underlying evidence gap: “People need to understand that there's a huge difference between peptides that have been rigorously studied and approved as medications… and these newer compounds. These other peptides haven't been adequately studied in humans and aren't approved by the Food and Drug Administration.”[3]

That evidence gap compounds an analytical chemistry problem. In the peer-reviewed literature on peptide therapeutics, aggregation — the self-association of peptide monomers into dimers, larger oligomers and sub-visible particles — is tracked as a critical quality attribute precisely because unverified or poorly controlled manufacturing conditions make it more likely, and it is not something a buyer can see or assess without laboratory testing such as SEC-HPLC or dynamic light scattering.[4] An anonymous vendor paid in untraceable crypto, sourcing from an unnamed manufacturer, offers no way to confirm any of this batch-to-batch.

How Should Researchers Verify a Peptide Supplier?

None of this is a guarantee, and no amount of vendor vetting substitutes for a researcher's own in-house verification where that's appropriate. But it is the difference between a documented reagent and a vial with an unknown, unverifiable origin.

Does This Affect Velox Peptides or the UK Legal Position?

No. This reporting concerns anonymous, largely US-facing online vendors operating outside any verifiable supply chain. Velox Peptides supplies compounds as HPLC-verified (≥99% purity) in vitro research reagents, with batch documentation available on request, and is a registered UK company under the Human Medicines Regulations 2012 framework covered in our guide on whether research peptides are legal in the UK. It is a separate position from the vendors this article reports on, and separate again from the US 503A/503B compounding process covered in our peptide compounding grey-market report.

These compounds are supplied as research reagents only. They are not medicines and have not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions